Influence of low tumor content on tumor mutational burden estimation by whole‐exome sequencing and targeted panel sequencing

BACKGROUND: Tumor mutational burden (TMB) is a promising biomarker for stratifying patient subpopulation who would benefit from immune checkpoint blockade (ICB) therapies. Although great efforts have been made for standardizing TMB measurement, mutation calling and TMB quantification can be challeng...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wenxin, Wang, Ruixia, Fang, Huan, Ma, Xiangyuan, Li, Dan, Liu, Tao, Chen, Zhenxi, Wang, Ke, Hao, Shiguang, Yu, Zicheng, Chang, Zhili, Na, Chenglong, Wang, Yin, Bai, Jian, Zhang, Yanyan, Chen, Fang, Li, Miao, Chen, Chao, Wei, Liangshen, Li, Jinghua, Chang, Xiaoyan, Qu, Shoufang, Yang, Ling, Huang, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102856/
https://www.ncbi.nlm.nih.gov/pubmed/34047470
http://dx.doi.org/10.1002/ctm2.415

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8102856/
https://www.ncbi.nlm.nih.gov/pubmed/34047470
http://dx.doi.org/10.1002/ctm2.415

Ejemplares similares